Ovarian Cancer Clinical Trials in Grand Rapids, Michigan

10 studies are recruiting for ovarian cancer in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

2. Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

   This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-g…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Corewell Health, Grand Rapids, Michigan

   Locations

   232 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06819007 on ClinicalTrials.gov

3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids, Michigan

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

4. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest /ID# 283487, Grand Rapids, Michigan

   Locations

   3 in total

   Run by

   AbbVie

   See if you can join NCT07807956 on ClinicalTrials.gov

5. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research - Midwest, Grand Rapids, Michigan

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

6. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

   This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   BAMF Health, Grand Rapids, Michigan

   Locations

   5 in total

   Run by

   Radiopharm Theranostics, Ltd

   See if you can join NCT07189871 on ClinicalTrials.gov

7. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Grand Rapids, Michigan

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

8. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

   HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - Midwest, Grand Rapids, Michigan

   Locations

   12 in total

   Run by

   Whitehawk Therapeutics, Inc.

   See if you can join NCT07444814 on ClinicalTrials.gov

9. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

   This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   15 in total

   Run by

   OnCusp Therapeutics, Inc.

   See if you can join NCT06234423 on ClinicalTrials.gov

10. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    6 in total

    Run by

    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov